Tazobactam Sodium — Active Pharmaceutical Ingredient

Tazobactam Sodium is an active pharmaceutical ingredient found in 5 FDA-approved drug products. Forms: INJECTABLE, POWDER. Routes: INJECTION, INTRAVENOUS.

Drug Ingredients A–Z 2 min read
This content is for informational purposes only. Always consult a healthcare professional.

Tazobactam Sodium (5 brand names, 2 dosage forms, 2 routes)

Available dosage forms: INJECTABLE, POWDER.

Routes of administration: INJECTION, INTRAVENOUS.

Brand Names

  • PIPERACILLIN AND TAZOBACTAM
  • PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
  • ZERBAXA
  • ZOSYN
  • ZOSYN IN PLASTIC CONTAINER

Contraindications

ZOSYN is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors.

Adverse Reactions

The following clinically significant adverse reactions are described elsewhere in the labeling: •Hypersensitivity Adverse Reactions [see Warnings and Precautions (5.1)] •Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] •Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5.3)] •Rhabdomyolysis [see Warnings and Precautions (5.4)] •Hematologic Adverse Reactions [see Warnings and Precautions (5.5) ] •Central Nervous System Adverse Reactions [see Warnings and Precautions (5.6) ] •Nephrotoxicity in Critically Ill Patients [see Warnings and Precautions (5.7) ] • Clostridioides difficile-Associated Diarrhea [see Warnings and Precautions (5.9) ]

Mechanism of Action

ZOSYN is an antibacterial drug [see Microbiology (12.4)].

Overdosage

There have been postmarketing reports of overdose with piperacillin and tazobactam. The majority of those events experienced, including nausea, vomiting, and diarrhea, have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or seizures if higher than recommended doses are given intravenously (particularly in the presence of renal failure) [see Warnings and Precautions (5.6) ]. Treatment should be supportive and symptomatic according to the patient’s clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis. Following a single 3.375 g dose of piperacillin and tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively [see Clinical Pharmacology (12)].

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.